Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression

Étienne Becht, Nicolás A. Giraldo, Laetitia Lacroix et al. · Genome biology · 2016 · 4K citations · Full text

Medicine, Immunology, Oncology +17

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger et al. · The Lancet · 2016 · 2.8K citations

Medicine, Oncology, Pharmacology +12

B cells and tertiary lymphoid structures promote immunotherapy response

Beth A. Helmink, Sangeetha M. Reddy, Jianjun Gao et al. · Nature · 2020 · 2.7K citations · Full text

Life Sciences, Cell Biology, Immunology +16